Clinical impact of perirenal thickness on short- and long-term outcomes of gastric cancer after curative surgery

Kojiro Eto1,2 | Naoya Yoshida1 | Masaaki Iwatsuki1 | Shiro Iwagami1 | Kenichi Nakamura2 | Keisuke Morita2 | Satoshi Ikeshima2 | Kei Horino2 | Shinya Shimada2 | Hideo Baba1

1Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2Department of Surgery, Japan Community Health care Organization Kumamoto General Hospital, Yatsushiro, Japan

Correspondence
Hideo Baba, Department of Gastroenterological Surgery, Kumamoto University, Graduate School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan. Email: hdobaba@kumamoto-u.ac.jp

Abstract
Background: A variety of factors for short- and long-term outcomes have been reported after radical resection for gastric cancer (GC). Obesity and emaciation had been reported to be a cause of poor short- and long-term outcomes with gastrointestinal cancer. However, the indicators are still controversial. The purpose of this study was to evaluate the relationship between perirenal thickness (PT) and short- and long-term outcomes after radical surgery for GC.

Methods: We analyzed the data of 364 patients with GC who underwent radical surgery. We evaluated the distance from the anterior margin of the quadratus lumborum muscle to the dorsal margin of the left renal pole using computed tomography (CT) as an indicator of PT. The association between PT and clinicopathological factors and short- and long-term outcomes was evaluated.

Results: The PT data were divided into low, normal, and high groups by gender using the tertile value. We found that the PT low group was 121 patients, normal group was 121 patients, and high group was 122 patients. Multivariate analyses showed that the high PT group was an independent risk factor for a short-outcome after curative surgery in GC patients (odds ratio 2.163; 95% confidence interval [CI] 1.156–4.046; P = .016). And the low PT group was an independent risk factor for overall survival (hazard ratio 2.488; 95% CI 1.400–4.421; P = .0019) and relapse-free survival (hazard ratio 2.342; 95% CI 1.349–4.064; P = .0025) after curative surgery in GC patients.

Conclusion: Perirenal thickness is a simple and useful factor for predicting short- and long-term outcomes after radical surgery for GC.

Keywords
gastric cancer, perirenal fat, predictive marker, short- and long-term outcomes
1 | INTRODUCTION

Gastric cancer (GC) is the third-most common cancer and the second-most common cause of death worldwide. Radical surgery with lymphadenectomy offers a curative result for patients with resectable GC, and a variety of factors for short- and long-term outcomes have been reported.

Obesity is associated with postoperative complications and worse prognosis in patients with gastrointestinal cancer, and is regarded as a major technical limiting factor for surgery because of the substantial surgical difficulties caused by abundant visceral fat (VF) and a narrow operating field. Many reports have demonstrated that obesity and abundant VF are associated with worse surgical outcomes after various surgical procedures. In these reports, obesity was associated with increased surgery time, blood loss, and postoperative complications. Moreover, the negative impact of postoperative complications on overall survival (OS) and relapse-free survival (RFS) after radical surgery for GC has been reported and discussed. Similarly, emaciation has been reported to be a cause of poor short- and long-term outcomes from low nutrition and sarcopenia. The body mass index (BMI) is one such indicator of obesity and emaciation; however, it is controversial.

Hiki et al previously reported that the thickness of the adipose tissue dorsal to the left kidney correlated with the amount of VF and short outcome after laparoscopic distal gastrectomy for early GC. However, there is no report on the association between long-term outcome and perirenal thickness (PT). We hypothesized that when there is much PT, postoperative complications increase and when there is little PT, the long-term prognosis worsens from low nutrition and sarcopenia compared to when the PT is normal. The purpose of this study was to evaluate the relationship between perirenal thickness and short- and long-term outcomes after surgery for GC.

2 | PATIENTS AND METHODS

2.1 | Study subjects and outcomes

From January 2010 to December 2014, a total of 364 patients with GC underwent curative gastrectomy at the Department of Gastroenterological Surgery, Kumamoto University Hospital and the Department of Surgery, Kumamoto General Hospital. These patients were analyzed in this retrospective study. We excluded cases of neuroendocrine carcinoma (two cases), special types (five cases), and perioperative mortality (three cases) from this study. We retrospectively evaluated patients' perioperative characteristics, which were obtained from hospital and surgical records and included patient age, sex, BMI, comorbidities, blood test results, surgical time, blood loss, reconstruction method, and postoperative complications. Clinical staging was determined during preoperative examinations, which consisted of upper endoscopy, endoscopic ultrasonography, thoracoabdominal computed tomography (CT), barium radiography, and upper gastrointestinal endoscopic ultrasound. Pathological findings were defined according to the TNM classification (American Joint Committee on Cancer Staging Manual, 7th edition). The dates and causes of death were collected from follow-up data on the basis of clinical examinations performed every 3–6 month during the 5 years after surgery. Data collection and analysis were approved by the central Scientific Review Board of both hospitals (no. 2407).

Gastrectomy with lymphadenectomy was performed according to the Japanese Gastric Cancer Treatment Guidelines for GC. In accordance with our policy, patients with clinical stage (cStage) II or III GC underwent conventional open gastrectomy with D2 lymphadenectomy, while patients with cStage I GC underwent laparoscopic gastrectomy with D1+ lymphadenectomy. Patients with pathological stage (pStage) II or III GC, excluding pT3N0 cases, received adjuvant chemotherapy.

The primary outcome was overall survival. The secondary outcomes were postoperative complications rate and RFS. OS was defined as the interval from surgery to the date of death from any cause, or the last follow-up in living patients. RFS was defined as the interval from surgery to either the first recurrence or death from any cause.

2.2 | Definition of postoperative complications

The severity of postoperative complications was evaluated using the Clavien–Dindo classification system. We defined postoperative complications in this study as conditions classified as Clavien–Dindo grade II or higher, severe postoperative complications as Clavien–Dindo grade III or higher, and inflammatory complications such as anastomotic leakage, pancreatic fistula, intraabdominal infection, infection at the surgical site, and pneumonia.

2.3 | Measurement of the perirenal thickness

We evaluated the distance from the anterior margin of the quadratus lumborum muscle to the dorsal margin of the left renal pole using CT of the transverse section, 5-mm slice, and venous phase as in our previous article. We took our measurements using the left kidney because the position of the right kidney may be influenced by the position of the liver. We decided to take our measurement at the level where the left renal vein exits the kidney, and measured the distance from the anterior margin of the quadratus lumborum muscle to the dorsal margin of the left renal pole as an indicator of PT.

To clarify the relationship between PT and short- and long-term outcomes, we divided into low, normal, and high groups for PT date by using the tertile value. Since there are differences in the amount of VF between male and female, the present study was also analyzed separately for male and female.
2.4 | Statistics

The clinicopathological characteristics and laboratory data of the two groups were compared using the chi-squared test for categorical variables and the Mann–Whitney U-test for continuous variables. \( P < .05 \) was considered statistically significant. In the univariate and multivariate analyses, continuous variables, including the preoperative laboratory data, surgical duration time, and amount of bleeding, were divided by the median. We used the Cox proportional hazards model to assess the effects of covariates during both the univariate and multivariate analyses; the categorical covariates are listed in Table 3. We conducted multivariate analysis using factors with \( P < .05 \) in the univariate analysis. All tests were analyzed using JMP software (SAS Institute, Cary, NC, USA).

3 | RESULTS

3.1 | Cutoff value of perirenal thickness

In males, 76 patients were in the low group (PT: 0.4–6.1), 76 patients were in the normal group (PT: 6.2–14.1), and 76 patients were in the high group (PT: 14.2–38.8). Similarly, in females, 45 patients were in the low group (PT: 0.4–3.1), 45 patients were in the normal group (PT: 3.2–5.8), and 46 patients were in the high group (PT: 5.9–26.0). In total, we found that the PT low group was 121 patients, the PT normal group was 121 patients, and the PT high group was 122 patients.

3.2 | Patients’ and baseline characteristics

In terms of the preoperative factors, there was a significantly higher number of patients who were male in the PT high group. In terms of surgical factors, there was a significantly longer surgical time, higher amount of blood loss, and higher frequency of postoperative complications (including severe and inflammatory complications) in the PT high group. However, there was no significant difference in cStage, pStage, between the groups (Table 1).

3.3 | Risk factors for postoperative complications

Variables that achieved a probability value of .05 in the univariate analysis were included in a subsequent multivariate analysis to identify risk factors for postoperative complications. In the multivariate

| TABLE 1 | Association between patient characteristics and perirenal thickness of the 364 gastric cancer patients |
|---------|---------------------------------|-----------------|-----------------|-------------------------------------------------|
| Factors | Variable                        | Low             | Normal          | High              | \( P \)-value |
|---------|--------------------------------|-----------------|-----------------|--------------------|--------------|
| Age median, years | Median (range) | 68 (22–97) | 64 (27–91) | 70 (36–89) | .016 |
| Body mass index median, kg/m\(^2\) | Median (range) | 21.6 (13.4–32.3) | 21.4 (14.9–32.6) | 23.1 (16.6–35.1) | <.001 |
| Body mass index median, kg/m\(^2\) | <18.5/18.5/25/≥25 | 15/90/16 | 15/86/20 | 5/73/42 | <.001 |
| Comorbidity (%) | Present | 49 (40.5) | 53 (43.8) | 57 (47.1) | .584 |
| Preoperative total protein, g/dL | Median (range) | 7.0 (5.4–8.3) | 6.8 (5.0–8.8) | 7.1 (5.1–8.0) | .850 |
| Preoperative albumin, g/dL | Median (range) | 4.1 (2.5–4.9) | 4.0 (2.7–4.8) | 4.2 (2.6–4.9) | .258 |
| Clinical T, \( \text{n} \) | 1/2/3/4 | 65/15/20/20 | 78/10/16/16 | 67/16/21/17 | .650 |
| Clinical N, \( \text{n} \) | Present | 30 (25.2) | 27 (22.5) | 27 (22.7) | .860 |
| Clinical stage, \( \text{n} \) | I/II/III/IV | 77/24/18/1 | 84/21/14/1 | 81/25/15/0 | .826 |
| Operative approach, \( \text{n} \) | Open/Lap | 72/49 | 52/69 | 72/50 | .013 |
| Operative procedure, \( \text{n} \) | DG/PG/TG/other | 71/14/35/1 | 86/10/25/0 | 68/26/27/1 | .030 |
| Lymph node dissection, \( \text{n} \) | D1/D2 | 66/55 | 74/47 | 68/54 | .540 |
| Reconstruction | B1/RY/others | 47/59/15 | 48/63/10 | 48/47/27 | .071 |
| Surgical time, min | Median (range) | 273 (103–667) | 295.5 (140–716) | 305 (123–674) | .036 |
| Blood loss, mL | Median (range) | 149 (0–1975) | 125 (0–2916) | 230 (5–4510) | .0080 |
| Postoperative complications, \( \text{n} \) | Present | 31 (25.6) | 27 (22.3) | 47 (38.5) | .014 |
| Postoperative severe complications, \( \text{n} \) | Present | 15 (12.4) | 14 (11.6) | 36 (29.8) | <.001 |
| Postoperative inflammatory complications, \( \text{n} \) | Present | 20 (16.5) | 16 (13.2) | 40 (32.8) | <.001 |
| Pathological T, \( \text{n} \) | 1/2/3/4 | 59/13/24/25 | 69/13/19/20 | 63/11/31/17 | .476 |
| Pathological N, \( \text{n} \) | Present | 48 (39.7) | 40 (33.1) | 42 (34.7) | .538 |
| Pathological stage, \( \text{n} \) | I/II/III | 67/22/32 | 76/20/25 | 66/34/22 | .121 |
| Adjuvant chemotherapy, \( \text{n} \) | Present | 26 (21.5) | 24 (19.8) | 25 (20.7) | .951 |

\( ^a \)According to the International Union Against Cancer tumor, node, metastasis classification system (7th edition).
analysis, high blood loss (≥155 mL) and PT high (odds ratio 2.163; 95% confidence interval [CI] 1.156–4.046; \( P = .016 \)) were selected as independent predictive factors for postoperative complications in GC patients who underwent curative gastrectomy (Table 2). The low PT was not found to be a predictor of postoperative complications.

### 3.4 Survival outcomes

The median follow-up time was 1840 days for the entire population of 364 GC patients. The PT low and high groups had significantly poorer outcomes. The OS and RFS results in the two groups are

| TABLE 2 | Univariate and multivariate analysis of factors affecting postoperative complications in gastric cancer patients who underwent curative gastrectomy |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Factors            | Univariate analysis | Multivariate analysis |
|                   | OR     | 95% CI     | P-value | OR     | 95% CI     | P-value |
| Age                |         |            |         |         |            |         |
| <75 years          | 1.000   |            |         | 1.000   |            |         |
| ≥75 years          | 1.782   | 1.096-2.886 | .020    | 1.568   | 0.924-2.663 | .096    |
| Gender             |         |            |         |         |            |         |
| Female             | 1.000   |            |         | 1.000   |            |         |
| Male               | 1.653   | 1.024-2.718 | .040    | 1.526   | 0.875-2.660 | .136    |
| Body mass index    |         |            |         |         |            |         |
| ≥18.5 kg/m² <25 kg/m² | 1.000   |            |         | 1.000   |            |         |
| <18.5 kg/m²        | 1.171   | 0.551-2.487 | .682    | 1.347   | 0.651-2.691 | .901    |
| ≥25 kg/m²          | 1.942   | 1.147-3.288 | .014    | 1.072   | 0.565-2.034 | .833    |
| Comorbidity        |         |            |         |         |            |         |
| Absent             | 1.000   |            |         | 1.000   |            |         |
| Present            | 1.082   | 0.683-1.710 | .735    |         |            |         |
| Clinical stage<sup>a</sup> |         |            |         |         |            |         |
| I                  | 1.000   |            |         | 1.000   |            |         |
| II/III/IV          | 2.059   | 1.279-3.331 | .0030   | 1.524   | 0.812-2.858 | .189    |
| Operation time     |         |            |         |         |            |         |
| <295 min           | 1.000   |            |         | 1.000   |            |         |
| ≥295 min           | 1.942   | 1.223-3.110 | .0048   | 1.666   | 0.941-2.947 | .080    |
| Blood loss         |         |            |         |         |            |         |
| <155 mL            | 1.000   |            |         | 1.000   |            |         |
| ≥155 mL            | 2.873   | 1.787-4.694 | <.0001  | 2.233   | 1.141-4.368 | .019    |
| PT                 |         |            |         |         |            |         |
| Normal             | 1.000   |            |         | 1.000   |            |         |
| Low                | 0.787   | 0.481-1.286 | .338    | 1.198   | 0.634-2.264 | .579    |
| High               | 1.988   | 1.244-3.178 | .0041   | 2.163   | 1.156-4.046 | .016    |
| Lymph node dissection |       |            |         |         |            |         |
| D1+                | 1.000   |            |         | 1.000   |            |         |
| D2                 | 1.312   | 0.831-2.071 | .243    |         |            |         |
| Reconstruction     |         |            |         |         |            |         |
| Billroth I         | 1.000   |            |         | 1.000   |            |         |
| Others             | 2.465   | 1.502-4.147 | .0003   | 1.860   | 0.961-3.601 | .066    |
| Operative approach |         |            |         |         |            |         |
| Lap                | 1.000   |            |         | 1.000   |            |         |
| Open               | 1.777   | 1.112-2.851 | .015    | 1.212   | 0.578-2.570 | .604    |
| Operative procedure |        |            |         |         |            |         |
| DG                 | 1.000   |            |         | 1.000   |            |         |
| Others             | 1.545   | 0.973-2.451 | .065    |         |            |         |

<sup>a</sup>According to the International Union Against Cancer tumor, node, metastasis classification system (7th edition).
demonstrated in Figure 1A,B, respectively. In the multivariate analysis, the PT low was selected as an independent predictive factor for OS (hazard ratio 2.488; 95% CI 1.400–4.421; \( P = .0019 \), Table 3) and RFS (hazard ratio 2.342; 95% CI 1.349–4.064; \( P = .0025 \), Table 4) in GC patients who underwent curative gastrectomy. However, PT high was not selected as an independent predictive factor for OS and RFS in this cohort.

4 DISCUSSION

In the present study we demonstrated that PT is a simple and useful predictor for the short- and long-term outcomes after curative surgery in GC patients. Our results indicated that the high PT group was associated with a higher frequency of postoperative complications, and the low PT group was associated with a potentially worsening prognosis. To the best of our knowledge, this is the first report to reveal an association between PT and short- and long-term outcomes after radical surgery for GC. BMI is widely used as an indicator of obesity in clinical settings. A higher BMI has been associated with increased complications in several studies.\(^3\)\(^–\)\(^18\)

However, another study demonstrated that there was no difference in surgical outcomes on the basis of BMI.\(^19\) These results show that the issue of whether BMI is correlated with short-term outcomes remains controversial. Because BMI is calculated using body weight and height, it considers not only the VF but also the subcutaneous fat. This makes it impossible to distinguish between the two using this indicator alone. Therefore, we considered that BMI may not be suitable for measuring obesity in surgical patients and that VF volume is more indicative of obesity. However, the precise measurement of the entire VF volume requires specialized software. The method of measuring VF using CT scans and an image processing 3-D image analysis system (eg: SYNAPSE VINCENT, DICOM images) is complex and is not suited to routine medical practice. Therefore, we focused on PT as a simple indicator of VF. This study revealed that CT assessment of PT, which was validated as a surrogate of VF, was superior to BMI for GC patients. The simplicity with which PT can be measured makes it a clinically valuable tool. Using PT, surgical teams can assess the risk of complications before surgery.

Several recent studies revealed that the occurrence of postoperative complications could have a significantly negative impact on the prognosis of patients with GC.\(^4\)\(^–\)\(^6\)\(^,\)\(^20\) Therefore, it is important to prevent the occurrence of complications, and prediction of morbidities before surgery is considered an important task, especially in patients with malignancy. Indeed, this study revealed that postoperative complications were an independent prognostic factor after radical surgery for GC. In this study, high PT was an independent predictor of short-term postoperative outcome, while it tended to be associated with a worse prognosis but was not an independent prognostic factor. Analysis of subgroups suggests that even high PT may not worsen the long-term outcome without postoperative complications (Figure S1). This suggests that the high level of recruitable energy from intraabdominal fat tissue may have prevented the prognosis from worsening.\(^21\)

We found that the low PT group was associated with long-term outcomes after radical surgery for GC. The relationship between prognosis and the low PT content may be attributed to several factors. First, the low PT might reflect a malnutrition state. Emaciated patients may suffer from malnutrition in the early stage of postoperative body weight loss compared with normal patients. Second, VF is an energy store that correlates with physical capacity, suggesting that the low PT reserves affect cancer prognosis. Obese patients have a large energy

![Figure 1A](image1.png)

**FIGURE 1** (A) Kaplan–Meier analysis of overall survival in the normal, low, and high perirenal thickness (PT) groups after resection of gastric cancer with curative intent. (B) Kaplan–Meier analysis of relapse-free survival in the normal, low, and high PT groups after resection of gastric cancer with curative intent
TABLE 3 Univariate and multivariate analysis of factors affecting overall survival in gastric cancer patients who underwent curative gastrectomy

| Factors                          | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR  | 95% CI    | P-value  | HR  | 95% CI    | P-value  |
| **Age**                         |     |           |          |     |           |          |
| <75 years                       | 1.00|           |          | 1.00|           |          |
| ≥75 years                       | 3.04| 1.966–4.698| <.0001   | 2.87| 1.861–4.434| <.0001   |
| **Gender**                      |     |           |          |     |           |          |
| Female                          | 1.00|           |          | 1.00|           |          |
| Male                            | 1.87| 1.163–3.109| .0090    | 1.53| 0.947–2.475| .082    |
| **Body mass index**             |     |           |          |     |           |          |
| ≥18.5 < 25 kg/m²                | 1.00|           |          | 1.00|           |          |
| <18.5 kg/m²                     | 1.79| 0.726–4.413| .206     | 0.98| 0.377–2.557| .970    |
| ≥25 kg/m²                       | 1.94| 1.258–3.014| .011     | 1.31| 0.778–2.207| .310    |
| **Comorbidity**                 |     |           |          |     |           |          |
| Absent                          | 1.00|           |          | 1.00|           |          |
| Present                         | 1.04| 0.672–1.610| .852     | 1.53| 0.947–2.475| .082    |
| **Operation time**              |     |           |          |     |           |          |
| <295 min                        | 1.00|           |          | 1.00|           |          |
| ≥295 min                        | 1.03| 0.661–1.605| .888     | 1.53| 0.947–2.475| .082    |
| **Blood loss**                  |     |           |          |     |           |          |
| <155 mL                         | 1.00|           |          | 1.00|           |          |
| ≥155 mL                         | 2.84| 1.790–4.672| <.0001   | 1.53| 0.869–2.706| .140    |
| **PT**                          |     |           |          |     |           |          |
| Normal                          | 1.00|           |          | 1.00|           |          |
| Low                             | 1.80| 1.197–2.726| .0048    | 2.49| 1.400–4.421| .0019   |
| High                            | 1.15| 0.753–1.756| .518     | 1.49| 0.809–2.745| .201    |
| **Lymph node dissection**       |     |           |          |     |           |          |
| D1+                             | 1.00|           |          | 1.00|           |          |
| D2                              | 1.94| 1.250–3.040| .0030    | 1.26| 0.788–2.017| .330    |
| **Reconstruction**              |     |           |          |     |           |          |
| Billroth I                      | 1.00|           |          | 1.00|           |          |
| Others                          | 1.87| 1.173–3.114| .0081    | 1.10| 0.577–2.110| .766    |
| **Operative procedure**         |     |           |          |     |           |          |
| DG                              | 1.00|           |          | 1.00|           |          |
| Others                          | 1.52| 1.015–2.303| .042     | 1.50| 0.884–2.558| .133    |
| **Postoperative complications** |     |           |          |     |           |          |
| Absent                          | 1.00|           |          | 1.00|           |          |
| Present                         | 2.30| 1.517–3.486| <.0001   | 1.84| 1.177–2.841| .0072   |
| **Pathological stage**          |     |           |          |     |           |          |
| I                               | 1.00|           |          | 1.00|           |          |
| II/III                          | 2.60| 1.671–4.127| <.0001   | 1.66| 1.052–2.628| .030    |

*According to the International Union Against Cancer tumor, node, metastasis classification system (7th edition).

store, which they can access in times of negative energy balance. Conversely, the basic physical capacity is much reduced in patients with low VF reserves and should present as a poor prognostic feature.

Previous studies reported various systems for predicting surgical risks. The physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM), modified POSSUM, and the estimation of physiological ability and surgical stress scoring system have been reported to provide reliable predictive scores for mortality and morbidity. Although these scoring systems are useful, they use both preoperative and
TABLE 4 Univariate and multivariate analysis of factors affecting relapse-free survival in gastric cancer patients who underwent curative gastrectomy

| Factors                      | Univariate analysis |          | Multivariate analysis |          |
|------------------------------|---------------------|----------|-----------------------|----------|
|                              | HR                  | 95% CI   | P-value               | HR       | 95% CI   | P-value   |
| Age                          |                     |          |                       |          |          |          |
| <75 years                    | 1.000               |          |                       | 1.000    |          |          |
| ≥75 years                    | 2.710               | 1.802-4.065 | <.001                 | 2.456    | 1.627-3.708 | <.001    |
| Gender                       |                     |          |                       |          |          |          |
| Female                       | 1.000               |          |                       | 1.000    |          |          |
| Male                         | 1.917               | 1.230-3.087 | .0036                | 1.603    | 1.013-2.535 | .044    |
| Body mass index              |                     |          |                       |          |          |          |
| ≥18.5 < 25 kg/m²             | 1.000               |          |                       | 1.000    |          |          |
| <18.5 kg/m²                  | 0.481               | 0.196-1.183 | .111                | 0.952    | 0.367-2.470 | .952    |
| ≥25 kg/m²                    | 2.164               | 1.431-3.273 | .0003               | 1.432    | 0.877-2.338 | .151    |
| Comorbidity                  |                     |          |                       |          |          |          |
| Absent                       | 1.000               |          |                       | 1.000    |          |          |
| Present                      | 1.075               | 0.714-1.612 | .728               |          |          |          |
| Operation time               |                     |          |                       |          |          |          |
| <295 min                     | 1.000               |          |                       | 1.000    |          |          |
| ≥295 min                     | 1.090               | 0.721-1.646 | .681               |          |          |          |
| Blood loss                   |                     |          |                       |          |          |          |
| <155 mL                      | 1.000               |          |                       | 1.000    |          |          |
| ≥155 mL                      | 3.034               | 1.962-4.826 | <.001              | 1.445    | 0.841-2.483 | .183    |
| PT                           |                     |          |                       |          |          |          |
| Normal                       | 1.000               |          |                       | 1.000    |          |          |
| Low                          | 1.581               | 1.064-2.349 | .024               | 2.342    | 1.349-4.064 | .0025   |
| High                         | 1.307               | 0.877-1.947 | .189               | 1.653    | 0.933-2.929 | .085    |
| Lymph node dissection        |                     |          |                       |          |          |          |
| D1+                          | 1.000               |          |                       | 1.000    |          |          |
| D2                           | 2.264               | 1.500-3.463 | <.001              | 1.444    | 0.923-2.260 | .107    |
| Reconstruction               |                     |          |                       |          |          |          |
| Billroth I                   | 1.000               |          |                       | 1.000    |          |          |
| Others                       | 1.982               | 1.274-3.179 | .0021              | 1.065    | 0.581-1.955 | .838    |
| Operative procedure          |                     |          |                       |          |          |          |
| DG                           | 1.000               |          |                       | 1.000    |          |          |
| Others                       | 1.491               | 1.008-2.207 | .046               | 1.418    | 0.859-2.343 | .172    |
| Postoperative complications  |                     |          |                       |          |          |          |
| Absent                       | 1.000               |          |                       | 1.000    |          |          |
| Present                      | 2.171               | 1.455-3.238 | .0001              | 1.768    | 1.156-2.704 | .0086   |
| Pathological stage<sup>a</sup>|                     |          |                       |          |          |          |
| I                            | 1.000               |          |                       | 1.000    |          |          |
| II/III                       | 2.643               | 1.749-4.054 | <.001              | 1.677    | 1.088-2.585 | .019    |

<sup>a</sup>According to the International Union Against Cancer tumor, node, metastasis classification system (7th edition).

Intraoperative factors to predict postoperative morbidity and mortality. The strength of the risk prediction score proposed in the current study is that it relies solely on the preoperative risk factors. A previous study evaluated the efficacy of perioperative exercise programs in reducing postoperative complications after surgery in overweight or obese GC patients. In patients with high PT, exercise interventions, and in patients with low PT, nutritional interventions may improve not only short-term outcomes but also long-term outcomes after curative surgery in GC patients.
This study had several limitations. First, this study was a retrospective analysis, and thus might be subject to several biases. Second, the cutoff values used in this study may differ from those applied at other institutions; the present study analyzed continuous variables of only two institutions. Different institutions may have different cutoff values. Therefore, a prospective multi-institutional study is desirable to validate the present findings. Interobserver reliability for these types of measurements needs to be demonstrated in further multi-institutional studies. Third, this study only focused on the score at one point before surgery, and we also need to analyze cases with exercise and/or nutritional interventions in the future.

In conclusion, this study is the first to reveal the association between PT and short- and long-term outcomes after curative surgery in GC patients. When we are able to undertake appropriate preoperative evaluations using PT, it will be possible to minimize complications to the greatest possible extent and may improve prognosis.

ACKNOWLEDGMENTS
We thank H. Nikki March, PhD, Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this article.

DISCLOSURE
Conflict of Interest: The authors declare that they have no conflicts of interest.

Author Contributions: Study concept and design: K. Eto, N. Yoshida, and H. Baba; acquisition of data: K. Eto, N. Yoshida; analysis and interpretation of data: K. Eto, N. Yoshida; writing of the article: K. Eto, N. Yoshida, and H. Baba. All authors approved the final article.

Ethical approval: The data collection and analysis of this study were approved by the institutional Scientific Review Board of Kumamoto University Hospital (No. 1037).

Informed consent: Informed consent was obtained from all individual participants included in the study.

ORCID
Naoya Yoshida https://orcid.org/0000-0002-8447-5278
Masaaki Iwatsuki https://orcid.org/0000-0002-0886-4618
Hideo Baba https://orcid.org/0000-0002-3474-2550

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Bege T, Leong B, Franco D, Turrini O, Guiramand J, Delpero JR. Impact of obesity on short-term results of laparoscopic rectal cancer resection. Surg Endosc. 2009;23:1460–4.
3. Kunisaki C, Makino H, Takagawa R, Sato K, Kawamura M, Kanazawa A, et al. Predictive factors for surgical complications of laparoscopic-assisted distal gastrectomy for gastric cancer. Surg Endosc. 2009;23:2085–93.
4. Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575–83.
5. Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, et al. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014;21:891–8.
6. Wang S, Xu L, Wang Q, Li J, Bai B, Li Z, et al. Postoperative complications and prognosis after radical gastrectomy for gastric cancer: a systematic review and meta-analysis of observational studies. World J Surg Oncol. 2019;17:52.
7. Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, et al. Sarcopenia impacts on short- and long-term results of hepatocellular carcinoma. Ann Surg. 2015;261:1173–83.
8. Ida S, Watanabe M, Yoshida N, Baba Y, Umezaki N, Harada K, et al. Sarcopenia is a predictor of postoperative respiratory complications in patients with esophageal cancer. Ann Surg Oncol. 2015;22:4432–7.
9. Taniguchi Y, Kurokawa Y, Takahashi T, Saito T, Yamashita K, Tanaka K, et al. Impacts of preoperative psoas muscle mass and visceral fat area on postoperative short- and long-term outcomes in patients with gastric cancer. World J Surg. 2021;45:815–21.
10. Zhao B, Zhang J, Mei D, Luo R, Lu H, Xu H, et al. Does high body mass index negatively affect the surgical outcome and long-term survival of gastric cancer patients who underwent gastrectomy: a systematic review and meta-analysis. Eur J Surg Oncol. 2018;44:1971–81.
11. Wang SL, Ma LL, Chen XY, Zhou DL, Li B, Huang DD, et al. Impact of visceral fat on surgical complications and long-term survival of patients with gastric cancer after radical gastrectomy. Eur J Clin Nutr. 2018;72:436–45.
12. Zhao W, Wang P, Sun W, Gu P, Wang X, Wu Z, et al. Effects of a high body mass index on the short-term outcomes and prognosis after radical gastrectomy. Surg Today. 2021;51(7):1169–78.
13. Eto K, Ida S, Ohashi T, Kumagai K, Nunobe S, Ohashi M, et al. Perirenal fat thickness as a predictor of postoperative complications after laparoscopic distal gastrectomy for gastric cancer. BJ Open. 2020;4:865–72.
14. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
15. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.
16. Sano T, Sasaki M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy–Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22:2767–73.
17. Kodera Y, Sasaki M, Yamamoto S, Sano T, Nashimoto A, Kurita A, et al. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg. 2005;92:1103–9.
18. Bickenbach KA, Denton B, Gonen M, Brennan MF, Coit DG, Strong VE. Impact of obesity on perioperative complications and long-term survival of patients with gastric cancer. Ann Surg Oncol. 2013;20:780–7.
19. Shimada S, Sawada N, Ishiyama Y, Nakahara K, Maeda C, Mukai S, et al. Impact of obesity on short- and long-term outcomes of laparoscopic-assisted distal gastrectomy for gastric cancer. Surg Endosc. 2018;32:358–66.
20. Pucher PH, Aggarwal R, Qurasli M, Darzi A. Meta-analysis of the effect of postoperative in-hospital morbidity on long-term patient survival. Br J Surg. 2014;101:1499–508.
21. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10:433–42.
22. Harada K, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, Izumi D, et al. Low visceral fat content is associated with poor prognosis in
a database of 507 upper gastrointestinal cancers. Ann Surg Oncol. 2015;22:3946–53.

23. Luna A, Rebasa P, Navarro S, Montmany S, Coroleu D, Cabrol J, et al. An evaluation of morbidity and mortality in oncologic gastric surgery with the application of POSSUM, P-POSSUM, and O-POSSUM. World J Surg. 2009;33:1889–94.

24. Otsuka Y, Kunisaki C, Ono H, Yamada R, Matsuda G, Nomura M, et al. Modified POSSUM to predict postoperative morbidity following gastrectomy. Hepatogastroenterology. 2007;54:1142–5.

25. Ariake K, Ueno T, Takahashi M, Goto S, Sato S, Akada M, et al. E-PASS comprehensive risk score is a good predictor of postsurgical mortality from comorbid disease in elderly gastric cancer patients. J Surg Oncol. 2014;109:586–92.

26. Cho H, Yoshikawa T, Oba MS, Hirabayashi N, Shirai J, Aoyama T, et al. Matched pair analysis to examine the effects of a planned preoperative exercise program in early gastric cancer patients with metabolic syndrome to reduce operative risk: the Adjuvant Exercise for General Elective Surgery (AEGES) study group. Ann Surg Oncol. 2014;21:2044–50.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Eto K, Yoshida N, Iwatsuki M, Iwagami S, Nakamura K, Morita K, et al. Clinical impact of perirenal thickness on short- and long-term outcomes of gastric cancer after curative surgery. Ann Gastroenterol Surg. 2022;6:496–504. doi:10.1002/ags3.12547